Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 86,100 shares, a decline of 13.7% from the February 28th total of 99,800 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 114,700 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of Entera Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Perigon Wealth Management LLC acquired a new stake in Entera Bio in the 4th quarter valued at $325,000. Northern Trust Corp acquired a new stake in shares of Entera Bio in the fourth quarter valued at about $450,000. Parkman Healthcare Partners LLC grew its position in shares of Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the period. Finally, Knoll Capital Management LLC raised its position in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after purchasing an additional 2,000,000 shares during the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Tuesday, March 18th.

Entera Bio Stock Performance

ENTX remained flat at $1.68 on Thursday. 6,450 shares of the company’s stock were exchanged, compared to its average volume of 108,650. The company has a 50-day moving average price of $2.09 and a 200-day moving average price of $2.02. The company has a market cap of $76.31 million, a P/E ratio of -6.46 and a beta of 1.47. Entera Bio has a one year low of $1.41 and a one year high of $3.35.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. Analysts predict that Entera Bio will post -0.28 EPS for the current year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.